Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease
Repeatability and Utility of the Usual and Fast Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A growing body of evidence suggests that in individuals with chronic lung disease their walk speed is related to their daily function and quality of life. It is possible to assess their usual (routine) and fast walking speeds by getting them to walk in a flat hallway.
In individuals with chronic lung disease, we anticipate that their usual walk speed will be helpful in exercise prescription and use in multidimensional scoring systems. However, it is important to first determine the measurement properties of these two walk speeds.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6M 2J5
- Westpark Health Care Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical and spirometric diagnosis of COPD
- Able to provide written informed consent
Exclusion Criteria:
- Unstable cardiovascular disease
- Acute respiratory exacerbation within 4 weeks
- Neurologic or orthopedic limitation to walking
- Inability to comprehend instructions in English
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COPD patients
Usual and Fast Walking Speeds
|
Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors.
The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coefficient of repeatability for usual and fast walk speeds
Time Frame: At baseline and over 1 week period.
|
Participants will be asked to demonstrate their usual and fast walk speeds over the middle 10 meters of a 30 meter straight track using optical sensors and a hand-held stopwatch. Participants will be instructed to walk at their 'usual' and 'fast' speeds as standardized instructions. The walk test will be repeated after a 5 minute rest and then repeated on two subsequent days, at the same time of day, within one week. This will be simply observational in nature with no planned intervention aside for controlling walking environment. The primary outcome is going to report a change in walk speeds from baseline and at 1 and 2 days using repeated measures as described by Bland and Altman (reference below). |
At baseline and over 1 week period.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Agreement in walk speeds between optical sensors and stopwatch
Time Frame: Baseline and over 1 week of testing.
|
Assess agreement between the use of optical sensors and stop watch time for the usual and fast walk speeds.
|
Baseline and over 1 week of testing.
|
|
Agreement in the Bode Index using six minute walk distance and usual walk speed.
Time Frame: Baseline
|
To assess agreement in the calculated Bode Index using the six minute walk distance versus estimated usual walk speed distance over 6 minutes.
|
Baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Precision of achieving a targeted endurance time using the usual and fast walking speeds.
Time Frame: Baseline
|
The usual and fast walk speeds will be used to predict the test speed for a high-intensity constant-speed endurance test that will achieve an acceptable endurance time of 2-15 minutes.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Roger Goldstein, MD, FRCPC, Westpark Healthcare Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Goldstein_Walk_COPD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
NCT03745547CompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease
-
NCT05431218CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe
-
NCT05539547Not yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
NCT06629675RecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease
-
NCT04828837TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation
-
NCT02962999CompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease Mild
-
NCT05661435WithdrawnChronic Obstructive Pulmonary Disease (COPD)
-
NCT04759807CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT02518139CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT02512510CompletedChronic Obstructive Pulmonary Disease (COPD)
Clinical Trials on Usual and Fast Walking Speeds
-
NCT03898375Terminated
-
NCT01668602CompletedCerebrovascular Accident
-
NCT04521829Completed
-
NCT02062541CompletedFunctionally-Impaired Elderly
-
NCT03750097CompletedMultiple Sclerosis
-
NCT01696019CompletedCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment
-
NCT01573585CompletedStroke | Hemiparesis
-
NCT02257190CompletedDiabetes Mellitus, Type 2
-
NCT04301232CompletedPost-Op Complication | Lumbar Disc Disease